Fig. 1

HDAC regulates RUNX2 expression in cancer. A375, H1299, HCT-116, PC3, MDA-MB231, TPC1 and BCPAP cancer cell lines were tested for their RUNX2 expression levels by qRT-PCR (a). All cells were treated with low and high doses of tubacin (specific HDAC6 inhibitor) and two different pan-HDACi (SAHA and valproic acid), then proliferation (b) and RUNX2 expression levels (c) were evaluated. All cell lines were treated with specific siRNA against HDAC6, 48 h after transfection RUNX2 levels were assessed by qRT-PCR in all cell lines (d) and by Western Blot in TPC1 and MDA-MB231 as a representative control (e). For proliferation experiments, cell counts were performed at 24–48-72 h after treatment, graphs show a representative experiment performed in triplicate. Histograms represents the mean relative fold change +/− SD of treated cells compared to control cells. Each experiment represents the average of at least two independent replicates. * p < 0.05